Moderately bullish activity in Pfizer (PFE), with shares up 28c, or 1.1%, near $25.18. Options volume relatively light with 102k contracts traded ...

American pharma giant Pfizer ($PFE) leads the pack as pharmaceutical companies plan price increases for at least 350 branded ...

The latest trading day saw Pfizer (PFE) settling at $25.18, representing a +1.12% change from its previous close.

We regret to report that long term Pfizer Inc. (NYSE:PFE) shareholders have had that experience, with the share price ...

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Pfizer signaled Tuesday it expects a challenging 2026 as it invests in new products to offset declines in Covid-19 revenues while limiting shareholder payouts. Shares of the big drugmaker fell sharply ...

LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to ...

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click for this updated look at PFE stock.

Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, with more money and help from the Trump administration Pfizer won its fight to ...

Pfizer propels itself into the obesity-drug game with $4.9 billion deal to buy Metsera. Shares of Metsera Inc. were rocketing into record territory in early Monday trading after the developer of ...

Shares of Pfizer rose after The Wall Street Journal reported the company would reveal a plan later Tuesday alongside the Trump Administration to lower drug costs. The stock rose 4% to $24.82. It is ...